- Home
- WFG vs WGS Comparison
WFG vs WGS Comparison
Compare WFG & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | WGS |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFG | WGS |
|---|---|---|
| Price | $62.77 | $132.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $93.00 | ★ $138.13 |
| AVG Volume (30 Days) | 223.5K | ★ 389.0K |
| Earning Date | 02-11-2026 | 02-17-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $5,702,000,000.00 | $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | $9.45 | $23.53 |
| P/E Ratio | ★ N/A | $1,804.77 |
| Revenue Growth | N/A | ★ 50.50 |
| 52 Week Low | $57.34 | $55.17 |
| 52 Week High | $93.03 | $170.87 |
Technical Indicators
Market Signals| Indicator | WFG | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 36.17 |
| Support Level | $60.23 | $125.46 |
| Resistance Level | $61.51 | $143.95 |
| Average True Range (ATR) | 1.38 | 6.67 |
| MACD | 0.24 | -2.24 |
| Stochastic Oscillator | 96.09 | 15.79 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.